No headlines found.
Business Wire (Tue, 7-Apr 8:00 AM ET)
bioAffinity Technologies' CyPath Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
Business Wire (Wed, 1-Apr 8:00 AM ET)
Business Wire (Wed, 25-Mar 8:00 AM ET)
Business Wire (Tue, 17-Mar 7:45 AM ET)
Business Wire (Fri, 13-Mar 8:00 AM ET)
Business Wire (Tue, 10-Mar 7:47 AM ET)
Business Wire (Tue, 3-Mar 8:30 AM ET)
Business Wire (Wed, 25-Feb 8:30 AM ET)
Business Wire (Thu, 19-Feb 11:00 AM ET)
Clinical Utility of bioAffinity Technologies' CyPath Lung Test Demonstrated in Real-World Case Study
Business Wire (Tue, 17-Feb 8:00 AM ET)
Bioaffinity Technologies - Warrant trades on the stock market under the symbol BIAFW.
As of April 7, 2026, BIAFW stock price was flat at $0.37 with 46 million shares trading.
BIAFW has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, BIAFW traded as high as $2.90 and as low as $.05.
BIAFW has outperformed the market in the last year with a return of +66.4%, while the SPY ETF gained +31.9%. In the last 3 month period, BIAFW beat the market returning +5.7%, while SPY returned -4.5%. However, in the most recent 2 weeks BIAFW has underperformed the stock market by returning -33.3%, while SPY returned +0.6%.
BIAFW support price is $.25 and resistance is $.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIAFW shares will trade within this expected range on the day.
